Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results
Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...
The Motley Fool on MSN1d
Is Viking Therepautics a Buy Now?
Wall Street's been pounding the table on Viking Therapeutics because VK2735 could become the next and best dual ...
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
clinicaltrialsarena23h
Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Viking Therapeutics Offers An Obesity Drug for Healthy Adults
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
Why Viking Therapeutics Stock Plummeted After Soaring Today
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...